Avaxia Biologics receives patent for oral anti-TNF antibodies for treatment of IBD News-Medical.net Avaxia Biologics, Inc., a clinical-stage biopharmaceutical company developing gut-targeted therapeutics, announced today that the company was awarded U.S. Patent No. 8,647,626, entitled "Compositions Comprising TNF-specific Antibodies for Oral ... |
